Business Wire

PHENOM

9.11.2022 14:01:48 CET | Business Wire | Press release

Share
Phenom Intelligent Talent Experience Platform Delivered 449% ROI According to 2022 Total Economic Impact Study

Phenom today announced that a composite organization using its Intelligence Talent Experience platform to hire, develop and retain talent achieved a 449% return on investment over three years with a payback period of less than six months — equaling more than $24M in cost savings and business benefits — according to a commissioned Total Economic Impact™ (TEI) Study conducted by Forrester Consulting on behalf of Phenom.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221109005200/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Phenom Intelligent Talent Experience platform delivered 449% ROI according to 2022 Total Economic Impact study (Graphic: Business Wire)

As labor and talent markets continue to waver, companies are looking for solutions to counteract the volatility with more efficient, automated hiring and retention processes, and an enhanced overall experience that differentiates them from competitors.

The TEI study uncovered that with Phenom, a composite organization representative of interviewed customers standardized and streamlined hiring and retention processes and achieved the following benefits by the third year:

  • 25% decrease in time to fill (or time to hire), with 30% of that decrease attributable to Phenom. Phenom facilitated faster hiring by accelerating efforts to identify, engage, screen, and schedule interviews with candidates, and enabling the growth of more qualified candidate pools.
  • 30% increase in internal hires, with 70% of that increase attributable to Phenom. Phenom improved the organization's ability to fill open positions with quality internal candidates instead of hiring talent externally, decreasing costs of new-hire onboarding, training, and time to productivity.
  • 50% more efficient spending to attract talent, with 80% of that improvement attributable to Phenom. With Phenom, the organization gained insights enabling it to target spending on job boards and social media that surface high-quality candidates cost-effectively.
  • 11 recruiter hours saved per week. Phenom saved the organization’s recruiters time sourcing and nurturing candidate leads, communicating with candidates, scheduling candidate interviews, and analyzing where leads are in the hiring process and who ultimately gets hired.

“[Phenom’s] artificial intelligence-enabled capabilities are a key element of how Phenom helps stakeholders execute faster and better across the talent acquisition, development and retention journey,” the Forrester study states. It also notes, “Its AI-based functionality reduces the time to fill roles, increases internal mobility, drives more productive spending to attract talent, and enhances recruiter productivity. As a result, organizations that use Phenom [Intelligent Talent Experience] are better equipped to hire, develop and retain talent.”

Additional Findings From The Forrester Consulting Total Economic Impact™ Study

To construct the study, Forrester interviewed Phenom clients, identifying the challenges they experienced previously, and the benefits, costs, risks, and outcomes they witnessed while using the platform.

Prior to implementing Phenom, the companies faced the following recruitment, employee development and retention challenges:

  • Competition for talent.
  • External and internal expectations for the candidate experience.
  • Limited ability to build and benefit from a talent community.
  • Lack of tools to support internal mobility, development and employee retention.
  • Cost of vacancies.
  • Manual and inefficient TA processes.
  • Inadequate analytics around hiring processes, spending and outcomes.

The Forrester study determined Phenom’s platform not only assisted with these challenges, it had a direct impact on cost savings with a payback period of less than six months. Over three years, the composite organization experienced these benefits:

  • $16.9M saved by decreasing time to fill a position.
  • $6.7M saved by increasing internal mobility.
  • $3.7M saved from more efficient spending to attract talent.
  • $2.3M saved from improving recruiter productivity.

Additional benefits identified in the study:

  • Improved candidate experience that elevated an organization’s brand.
  • Increased satisfaction and retention of current employees.
  • Reduced spending on external recruiters.
  • Improved productivity around recruitment events.

What Customers Said About Phenom in the Forrester Study

“We wouldn’t be able to keep up with the competition without the functionality Phenom provides,” said a vice president of talent acquisition at an industrial equipment company. The interviewee also stated, “Now, we can make informed business decisions with data…so, Phenom’s analytics help us avoid unnecessary costs, build our budgets, and determine where to shift acquisition spending so we’re not wasting money.”

“Sourcing efforts that previously took two hours can be done in 30 minutes using the CRM, especially by using its AI,” revealed a director of talent acquisition strategy and operations at a healthcare organization.

“We now have 1.5 million people in our talent pool, which helps us a lot, especially with Phenom’s AI-driven skills and job matching,” reported a global HR systems manager at a logistics company.

“Phenom has absolutely changed where and on what we spend money, and when to attract talent,” said a senior director of talent acquisition for a transportation company.

Intelligent Talent Experience is Transformational

More than 500 global and diverse companies are already using the Phenom Intelligent Talent Experience platform to connect people, data and interactions to deliver phenomenal moments with maximum efficiency throughout the talent journey.

With Phenom:

  • Candidates find and choose the right job faster.
  • Employees develop their skills and evolve.
  • Recruiters become wildly productive.
  • Managers build stronger-performing teams.
  • HR aligns employee development with company goals.
  • HRIS easily integrates existing HR tech to create a holistic infrastructure.

“Hiring and retention is now the most critical conversation in the boardroom,” said Mahe Bayireddi, CEO and co-founder of Phenom. “As the margins of companies tighten, company leaders are turning to HR to identify considerable cost savings through more efficient ways to hire, develop and retain quality talent. Consolidating spend with a solution that cuts across the most critical areas of both talent acquisition and management is possible — but only by combining and delivering on three core elements: experience, intelligence and automation.”

To see the full TEI study, or to learn more about Phenom, visit: info.phenom.com/forrester-tei

About Phenom

Phenom has a purpose of helping a billion people find the right job. Through AI-powered talent experiences, employers are using Phenom to hire employees faster, develop them to their full potential, and retain them longer. The Phenom Intelligent Talent Experience platform seamlessly connects candidates, employees, recruiters, hiring managers, HR and HRIS — empowering over 500 diverse and global enterprises with innovative products including Phenom Career Site, Chatbot, CMS, CRM, AI Scheduling, Video Assessments, Campaigns, University Recruiting, Talent Marketplace, Career Pathing, Gigs, Mentoring, and Referrals.

Phenom has earned accolades including: Inc. 5000’s fastest-growing companies (3 consecutive years), Deloitte Technology's Fast 500 (4 consecutive years), Business Intelligence Group's Artificial Intelligence Excellence Awards (2021 & 2022), and a regional Timmy Award for launching and optimizing HelpOneBillion.com (2020).

Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.

For more information, please visit www.phenom.com. Connect with Phenom on LinkedIn, Twitter, Facebook, YouTube and Instagram.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005200/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye